StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Investment analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a note issued to investors on Sunday. The firm set a “sell” rating on the stock.

A number of other equities research analysts also recently commented on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Syros Pharmaceuticals has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Trading Up 6.2 %

Shares of SYRS stock opened at $0.22 on Friday. The company has a market capitalization of $5.90 million, a P/E ratio of -0.07 and a beta of 1.33. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The business’s 50 day moving average is $1.34 and its two-hundred day moving average is $3.03. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the previous year, the business earned ($1.35) earnings per share. Equities analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth about $34,000. Certuity LLC purchased a new position in Syros Pharmaceuticals during the second quarter worth approximately $109,000. Acadian Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the last quarter. Exome Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after buying an additional 163,234 shares during the period. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.